A change in the authority requirements for the cholinesterase inhibitors (donepezil hydrochloride, galantamine hydrochloride and rivastigmine hydrogen tartrate) means that the same cognitive test used in the initial treatment authority application must be used in requests for continued treatment. If the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-COG) score was not provided with the initial authority application this measurement cannot be used to demonstrate improved cognitive function (a decrease of at least 4 points from baseline on the ADAS-COG) for the purposes of continued treatment.